Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of “Buy” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given an average rating of “Buy” by the twenty-two analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nineteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $116.30.

Several brokerages recently weighed in on KYMR. Stephens upped their price objective on Kymera Therapeutics from $65.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, December 11th. Oppenheimer boosted their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Wednesday, October 8th. Bank of America lifted their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, B. Riley increased their price objective on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, December 22nd.

Kymera Therapeutics Trading Down 2.2%

NASDAQ KYMR opened at $73.09 on Thursday. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of -20.36 and a beta of 2.21. The firm’s 50 day simple moving average is $73.18 and its 200 day simple moving average is $57.26. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The firm had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. On average, equities research analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bruce Booth sold 229,809 shares of the stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $91.73, for a total value of $21,080,379.57. Following the completion of the transaction, the director directly owned 686,477 shares in the company, valued at approximately $62,970,535.21. This trade represents a 25.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker purchased 2,005,813 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $86.00 per share, for a total transaction of $172,499,918.00. Following the completion of the purchase, the director directly owned 7,955,916 shares of the company’s stock, valued at approximately $684,208,776. This represents a 33.71% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 510,471 shares of company stock worth $43,267,209 in the last ninety days. Insiders own 16.01% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its holdings in Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after acquiring an additional 540 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. grew its stake in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. increased its holdings in Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.